Presented by
Management Forum
The nasal cavity is an established pathway to treat local diseases as well as systemic conditions using small molecules. As the pharmaceutical industry shifts towards targeted biologics, the nasal cavity is also an attractive target for delivery of peptides, monoclonal antibodies, nucleic acids and stem cells. This is an ideal opportunity to hear from experts in the field of nasal drug delivery who will address topics such as: challenges associated with formulation, barriers to cell penetration and absorption, the pros and cons for liquid versus powder formulations, and strategies for maintaining stability and prolonging retention in the nasal cavity.
★★★★★ "Very clear and informative!"
The nasal cavity is an established pathway to treat local diseases as well as systemic conditions using small molecules. As the pharmaceutical industry shifts towards targeted biologics, the nasal cavity is also an attractive target for delivery of peptides, monoclonal antibodies, nucleic acids and stem cells. For example, an intranasal mAb formulation is in phase 1 clinical trials for progressive Multiple Sclerosis.
This course will address the challenges associated with formulation and clinical trial manufacture of biologics for delivery to the nasal cavity. The course will also highlight barriers to cell penetration and absorption and identification of an ideal target product profile.
The pros and cons for liquid versus powder formulations will be discussed. In addition, the course will focus on strategies for maintaining stability and prolonging retention in the nasal cavity. Device selection for preclinical and clinical studies using predictive tools such as nasal casts will be presented.
Finally, the session will help prepare the audience with manufacturing strategies for clinical trials with a nasally administered biologic.
This course is of our range of Medical Devices training courses - now also including Medical Devices Cyber Security training to help improve your data security.
Julie Suman, Aptar Pharma
David Farrow, Aptar Pharma
Lucas Silva, Nanopharm
Gemma Budd, Nanopharm
Dr. Julie D. Suman is the Vice President of Scientific Affairs for Aptar Pharma. She manages strategic scientific planning and Aptar’s Scientific Advisory Board. Dr. Suman is also the co-founder of Next Breath. She holds a B.S. in Pharmacy from Duquesne University (1996) and a Ph.D. in Pharmaceutical Sciences from the University of Maryland, Baltimore (2002). Dr. Suman serves on the External Advisory Committee of the New South Wales RNA Production and Research Network. In addition, she is a co-editor for Respiratory Drug Delivery Proceedings, an international symposium, and an Affiliate Assistant Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University.
Gemma is the General Manager of Nanopharm, an Aptar Pharma company, where she was originally Director of Business Development and now has full responsibility for the Nanopharm business - both operationally and commercially - to continue to drive growth and commercialize innovative services and scientific solutions within the specialist field of OINDP. With a background in molecular genetics and pharmacology, she has spent 15 years working in the pharmaceutical and medical devices industry ranging from clinical pathology, materials science, formulation development and drug delivery device design and manufacturing businesses, mostly in inhaled drug products, nasal sprays, and oral solid dosage forms. She has worked in laboratory, R&D, management and commercial positions at Astrazeneca, Lucideon, Bespak, Nolato and now Nanopharm.
Lucas Silva is a Molecular and Cellular Biologist by academic training from the University of Lisbon and currently is working as a Senior Specialist leading the Analytical services at Nanopharm, an Aptar Pharma company.
Prior to his experience in Nanopharm, Lucas did a research internship at University College London focused on the development of particle engineered Dry Powder Inhalers (DPIs) for pulmonary infections.
With over 8 years of immersion in the pharmaceutical industry, Lucas has cultivated expertise spanning analytical services, formulation technology, and drug delivery devices, predominantly within the realm of research and development, particularly in orally inhaled and nasal drug products.
His key research areas are the development of more realistic respiratory and nasal analytical methods, the application of specialized in vitro performance data to de-risk and accelerate drug product development.
Lucas has showcased his research findings at numerous international conferences through both poster presentations and podium talks. Additionally, he has contributed as a co-author to a peer-reviewed paper centred on enhancing impactor testing for assessing the bioequivalence of DPIs.
Currently, Lucas actively engages in discussions within the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS), contributing valuable insights to navigate the evolving landscape of inhaled and nasal drug products.
Very clear and informative!
Oct 10 2023
Serge PAMPFER
CEO, Maedia
Jun 6 2023
The webinar was an excellent overview and insight into an emerging field - good balance of market intel and technical detail.
Eleanor Catherine Canipa
Senior Business Development Manager, Nanopharm (an Aptar Company)
United States of America
United Kingdom
Israel
Italy
Argentina
Germany
Sweden
Australia
Belgium
Canada
Denmark
Switzerland
Multiple colleagues? See above for details of our discounts for 2, 3, or 4 delegates. For more, talk to one of our training experts to discuss how to: